Tetra Radar · FDA Approvals · Decision date
INO-3107: FDA decision date
Inovio Pharmaceuticals Inc. (INO) · 30 October 2026
In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.
Source: 10-Q of 12 August 2026
The FDA approved it on 30 October 2026.
The FDA approved VOCERYQ to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.
Inovio Pharmaceuticals Inc. on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.